Electra Therapeutics Prices Upsized $350M IPO to Fund Late-Stage Drug Development

South San Francisco, CA, September 17, 2026 (Globe Newswire) -- Electra Therapeutics has priced an upsized initial public offering of 23.3 million shares at $15 per share, generating approximately $350 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 3.5 million shares, potentially increasing the proceeds from the offering. Electra plans to use the capital to advance its clinical-stage pipeline, led by ipsoprubart (ELA026), which is being evaluated in a global registrational program for secondary hemophagocytic lymphohistiocytosis and in cancer.

Read full article here.